ALPHA-BETA WILL SEEK BETAFECTIN LICENSURE IN LIMITED PATIENT POPULATION
Executive SummaryAlpha-Beta Technology is designing a 300-patient confirmatory trial of Betafectin (PGG-glucan) in non-colorectal gastrointestinal surgery patients, which it hopes to present to FDA within the next six weeks at a meeting to discuss a PLA filing for Betafectin
You may also be interested in...
Number one ask is for congressional pressure to centralize rare disease expertise at the agency, but advocates also are preparing legislation that would mandate the new center.
FDA’s food, dietary supplement and cosmetics division seeks funding to support its artificial intelligence capabilities, including post-market surveillance and speedy interventions in instances where safety issues arise. Also of note, the agency cites UV filters’ effects on the skin microbiome as a research priority in its fiscal 2021 budget justification to Congress.
Catering to patients can help make clinical trials more accessible and useful, presenters argued at a recent conference.